ABSTRACT
PURPOSE: Anthracycline-based or platinum-based neoadjuvant chemotherapy belongs to the standard treatment for early-stage breast cancer (EBC) that is either triple-negative or human epidermal growth factor receptor 2 positive (HER2 +). Currently, there is a paucity of data comparing their impact on health-related quality of life (HRQoL). METHODS: Triple-negative or HER2 + EBC from our two prospective randomized controlled trials, neoCARH and neoCART, were divided into two groups based on the neoadjuvant chemotherapy regimens they received: anthracycline-based or platinum-based group. HRQoL was the exploratory endpoint in these two trials, which was assessed using the European Organization for Research and Treatment of Cancer Quality of Life-Core30 and Breast23 questionnaires. The primary variable of interest was the C30 summary score (C30-SumSc). Assessments were carried out at baseline, after neoadjuvant chemotherapy, and 1 year and 2 years after diagnosis. RESULTS: The mean questionnaires' compliance rate was 95.0%. After neoadjuvant chemotherapy, 210 patients had evaluable HRQoL data, the mean least square change from baseline for the platinum-based group was - 15.997 (95% confidence interval (CI): - 17.877 to - 14.117), and it was - 20.156 (95% CI: - 22.053 to - 18.258) for the anthracycline-based group (difference: 4.159, 95% CI: 1.462 to 6.855, P = 0.003, minimal important difference = 3). For the majority of the domains of interest assessed by the C30 and BR23 questionnaires, the platinum-based group demonstrated superior outcomes in comparison to the anthracycline-based group. CONCLUSION: Patients receiving platinum-based or anthracycline-based regimens both experienced worsened HRQoL after neoadjuvant chemotherapy; however, the former provided relatively better HRQoL compared with the latter. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT03140553. Registered 4 May 2017 (neoCARH). NCT03154749. Registered 16 May 2017 (neoCART).
Subject(s)
Anthracyclines , Antineoplastic Combined Chemotherapy Protocols , Breast Neoplasms , Neoadjuvant Therapy , Patient Reported Outcome Measures , Quality of Life , Humans , Female , Neoadjuvant Therapy/methods , Middle Aged , Anthracyclines/administration & dosage , Anthracyclines/therapeutic use , Breast Neoplasms/drug therapy , Breast Neoplasms/pathology , Adult , Prospective Studies , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Surveys and Questionnaires , Aged , Neoplasm Staging , Triple Negative Breast Neoplasms/drug therapy , Receptor, ErbB-2/metabolismABSTRACT
Four kinds of cold recycling (CR) mixtures with different asphalt emulsions were studied for their high-temperature performance in both binder properties and internal structures aspects. Digital image processing was introduced to determine the thickness spectrum for the asphalt mortar of the CR mixtures from a mesoscopic perspective. The time-temperature sweep (TTS) test was conducted to obtain the rheological parameters of each corresponding emulsified residue and the permanent deformation performance of each CR mixture was measured by dynamic creep test. A principle component analysis (PCA) was used to compare the typical performance parameters of the CR mixtures and find the factors controlling the rutting resistance of CR mixtures. The results show that the high-temperature performance of the CR mixtures with a modified emulsified asphalt showed improvements relative to the nominal case. Including Marshall stability, several parameters from the rheological properties of binder (G*/sinδ, flow number) and mortar thickness (max, range proportion 0-10 mm) could significantly influence the high-temperature performance and rutting resistance of the CR mixtures.
